eXmoor Pharma and UCL Join Forces to Enhance Gene Therapy Development

eXmoor Pharma has entered into a strategic collaboration with the Translational Research Office (TRO) at University College London (UCL) to expedite the development of innovative cell and gene therapies (CGTs). This partnership aims to bridge the gap between academic research and clinical application, ensuring that promising therapies transition more efficiently from the lab to patient care.

The collaboration focuses on fostering earlier engagement between UCL innovators and eXmoor’s multidisciplinary teams. By reducing the risks, costs, and complexities associated with the development of new technologies, both organizations anticipate a smoother pathway to clinical trial readiness.

Strengthening Innovation through Collaboration

Officials from eXmoor and UCL have emphasized their mutual commitment to navigating the technical and regulatory obstacles that frequently hinder the progress of CGT candidates. Through this partnership, academic teams at UCL will gain access to essential resources, including:

– Consulting on Chemistry, Manufacturing, and Controls (CMC) and regulatory strategies
– Laboratory capacity and expertise in process and analytical development
– Good Manufacturing Practice (GMP) manufacturing for early clinical studies
– Insights across various modalities such as viral vectors, autologous and allogeneic cell therapies, and RNA technologies

This structured early engagement is designed to help UCL researchers develop more commercially viable strategies. Opportunities for grant input, regular consultancy clinics, and collaborative events will facilitate the transition from academic innovation to GMP readiness.

Angela Osborne, founder and executive chair of eXmoor Pharma, stated, “The strength of the U.K.’s academic science has always been clear, but getting groundbreaking therapies from the lab to patients requires a collaborative approach. This partnership with UCL TRO reflects our shared belief that supporting translational research with practical, GMP-ready solutions is the key to unlocking meaningful outcomes for patients.”

Bridging the Gap Between Research and Application

Pamela Tranter, head of the Translational Research Group at the TRO, highlighted UCL’s commitment to driving innovation that has the potential to transform lives. “Through this strategic partnership, we look forward to connecting UCL researchers with eXmoor’s expertise, supporting closer collaboration with industry and the development of practical, scalable plans that could help realize therapeutic potential,” she remarked.

This collaboration is not only a significant step for both organizations but also represents a broader movement within the U.K. to enhance the translation of academic research into viable medical therapies. By aligning their capabilities and resources, eXmoor and UCL aim to contribute to a future where innovative treatments can be developed and delivered more effectively, benefiting patients in need of advanced therapies.